# Efficacy and Safety of Induction Benmelstobart Plus Anlotinib and Chemotherapy Followed by Concurrent Chemoradiotherapy and Benmelstobart Maintenance Versus Concurrent Chemoradiotherapy Followed by Benmelstobart Maintenance in Patients With Unresectable Stage III NSCLC

> **NCT07643350** · PHASE2 · NOT_YET_RECRUITING · sponsor: **The Third Xiangya Hospital of Central South University** · enrollment: 152 (estimated)

## Conditions studied

- NSCLC

## Interventions

- **BIOLOGICAL:** Benmelstobart
- **DRUG:** benmelstobart combined with chemotherapy and anlotinib

## Key facts

- **NCT ID:** NCT07643350
- **Lead sponsor:** The Third Xiangya Hospital of Central South University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-15
- **Primary completion:** 2029-05-15
- **Final completion:** 2031-05-15
- **Target enrollment:** 152 (ESTIMATED)
- **Last updated:** 2026-06-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07643350

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07643350, "Efficacy and Safety of Induction Benmelstobart Plus Anlotinib and Chemotherapy Followed by Concurrent Chemoradiotherapy and Benmelstobart Maintenance Versus Concurrent Chemoradiotherapy Followed by Benmelstobart Maintenance in Patients With Unresectable Stage III NSCLC". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07643350. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*